Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. Vilazodone may also be associated with less sexual dysfunction and weight gain. Vilazodone was given FDA approval on January 21, 2011.
用于治疗成人重度抑郁症(MDD)。
Christophe G Lambert, Albuquerque, New Mexico, United States
ATP Clinical Research, Costa Mesa, California, United States
Psychiatric Associates, Overland Park, Kansas, United States
Pharmsite Research Inc., Baltimore, Maryland, United States
Harmonex Neuroscience Research, Dothan, Alabama, United States
Woodland International Research Group, INC, Little Rock, Arkansas, United States
ATP Clinical Research, Costa Mesa, California, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Duke University Medical Center / Civitan Building, Durham, North Carolina, United States
New York State Psychiatric Institute, New York, New York, United States
Forest Investigative Site 054, Baltimore, Maryland, United States
Forest Investigative Site 034, Oakland Park, Florida, United States
Forest Investigative Site 030, Roswell, Georgia, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
University of Virginia, Charlottesville, Virginia, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Forest Investigative Site 023, Birmingham, Alabama, United States
Forest Investigative Site 013, Phoenix, Arizona, United States
Forest Investigative Site 001, Costa Mesa, California, United States
UT Southwestern Medical Center, Dallas, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.